{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:31:04Z","timestamp":1791405064166,"version":"4.3.3"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100020450","name":"Soochow University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.critrevonc.2024.104390","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T02:44:40Z","timestamp":1716345880000},"page":"104390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed\/refractory non-Hodgkin lymphoma: Current studies and future prospects"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-5326-8981","authenticated-orcid":false,"given":"Lingzi","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changju","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2024.104390_bib1","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.282804","article-title":"Salvage radiotherapy in relapsed\/refractory large B-cell lymphoma after failure of CAR Tcell therapy","author":"Ababneh","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104390_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2021-147568","article-title":"Novel agents may be preferable to chemotherapy for large B-cell lymphoma progressing after CD19-CAR-T: a multicenter observational study","volume":"138","author":"Alarcon Tomas","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib4","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1016\/j.ijrobp.2018.06.306","article-title":"Tandem induction radiation and chimeric antigen receptor T cell therapy in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"102","author":"Arscott","year":"2018","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1158\/1078-0432.CCR-21-3140","article-title":"Clinical impact of immune cells and their spatial interactions in diffuse large B-cell lymphoma microenvironment","volume":"28","author":"Autio","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib6","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","author":"Bethge","year":"2022","journal-title":"Blood 140, 349-58"},{"key":"10.1016\/j.critrevonc.2024.104390_bib7","first-page":"2230","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood\u00a0Adv."},{"key":"10.1016\/j.critrevonc.2024.104390_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijrobp.2009.04.036","article-title":"Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era","volume":"77","author":"Biswas","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S0167-8140(21)07302-3","article-title":"Feasibility and outcome of bridging RT pre CAR-T in DLBCL in one centre with a wide referral network","author":"Brady","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib10","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.25505","article-title":"Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy","volume":"94","author":"Chow","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-143442","article-title":"Bridging radiation is an effective strategy to control lymphoma in preparation for CAR-T: a city of hope experience","volume":"136","author":"Dandapani","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2017.02.190","article-title":"180 - Predictors of manufacturing (MFG) success for chimeric antigen receptor (CAR) T cells in Non-Hodgkin Lymphoma (NHL)","volume":"19","author":"Davis","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.critrevonc.2024.104390_bib13","first-page":"3268","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood\u00a0Adv."},{"key":"10.1016\/j.critrevonc.2024.104390_bib14","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","article-title":"Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape","volume":"26","author":"DeSelm","year":"2018","journal-title":"Mol. Ther.\u00a0J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.critrevonc.2024.104390_bib15","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.prro.2019.09.010","article-title":"CAR-T cell therapy for lymphoma: how does radiation therapy fit in?","volume":"10","author":"Dreyfuss","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib16","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.ijrobp.2021.06.038","article-title":"Patterns and predictors of failure in recurrent or refractory large B-cell lymphomas after chimeric antigen receptor T-cell therapy","volume":"111","author":"Figura","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/tlcr.2017.03.07","article-title":"Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART)","volume":"6","author":"Flynn","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib18","first-page":"1462","article-title":"Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication","volume":"62","author":"Ganss","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib20","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.2007.15.4773","article-title":"Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity","volume":"26","author":"Hoppe","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.021","article-title":"Bridging radiation rapidly and effectively cytoreduces high-risk relapsed\/refractory aggressive b cell lymphomas prior to chimeric antigen receptor T cell therapy","author":"Hubbeling","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2024.104390_bib22","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib23","article-title":"MSKCC early experience using radiotherapy As a bridging strategy for relapsed diffuse large B cell lymphoma before CD19 CAR T therapy","volume":"134","author":"Imber","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-140991","article-title":"Clinical impact of bridging therapy prior to commercial chimeric antigen receptor (CAR) T-cell therapies for relapsed\/refractory lymphomas","volume":"136","author":"Imber","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/bjh.16541","article-title":"Early experience using salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy","volume":"190","author":"Imber","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib26","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-117133","article-title":"Radiation therapy As a bridging strategy for refractory diffuse large B cell lymphoma patients awaiting CAR T manufacturing of axicabtagene ciloleucel","volume":"132","author":"Jain","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3324\/haematol.2022.281954","article-title":"Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response","volume":"108","author":"Jallouk","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104390_bib28","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.ijrobp.2021.07.296","article-title":"Radiotherapy bridging in patients With R\/R high-grade lymphoma receiving CD19 CAR-T in the UK","volume":"111","author":"Kuhnl","year":"2021","journal-title":"Int. J. Radiat. Oncol.\u00a0Biol.\u00a0Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2024.104390_bib30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3390\/cancers15061747","article-title":"Long-term follow-up of bridging therapies prior to CAR T-cell therapy for relapsed\/refractory large B cell lymphoma","volume":"15","author":"Ladbury","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2024.104390_bib31","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.ijrobp.2019.06.514","article-title":"Induction radiation prior to commercial chimeric antigen receptor T-cell therapy for relapsed\/refractory non-hodgkin lymphoma","volume":"105","author":"LaRiviere","year":"2019","journal-title":"Int. J. Radiat. Oncol., Biol., Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib34","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","article-title":"Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity","volume":"180","author":"Lugade","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.17738","article-title":"The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma","volume":"195","author":"Lutfi","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib36","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2005.09.030","article-title":"Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma","volume":"64","author":"Martens","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib37","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/S1470-2045(19)30461-9","article-title":"Enhancing CAR T-cell therapy through cellular imaging and radiotherapy","volume":"20","author":"Minn","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib38","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib39","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ijrobp.2017.12.005","article-title":"Role of radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma: guidelines from the international lymphoma radiation oncology group","volume":"100","author":"Ng","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib42","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib43","first-page":"2871","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood\u00a0Adv."},{"key":"10.1016\/j.critrevonc.2024.104390_bib44","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib45","first-page":"32","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J. Immunol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib46","article-title":"Analysis of patterns of failure and the role of bridging radiation therapy in patients with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) treated with CAR T-cell therapy","volume":"111","author":"Ravella","year":"2021","journal-title":"Int. J. Radiat. Oncol.\u00a0Biol.\u00a0Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib47","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib48","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","author":"Roddie","year":"2023","journal-title":"Blood\u00a0Adv."},{"key":"10.1016\/j.critrevonc.2024.104390_bib49","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T Cells and crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.radonc.2021.11.031","article-title":"Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?","volume":"166","author":"Saifi","year":"2022","journal-title":"Radiother. Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2024.104390_bib51","first-page":"03637","article-title":"Don't Put the CART Before the Horse: the role of radiation therapy in Peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma","volume":"S0360-3016","author":"Saifi","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib53","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/imt.15.65","article-title":"Strategies for combining immunotherapy with radiation for anticancer therapy","volume":"7","author":"Seyedin","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2024.104390_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.02.021","article-title":"Assessment of salvage regimens post-chimeric antigen receptor T cell therapy for patients with diffuse large B cell lymphoma","volume":"28","author":"Sigmund","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.critrevonc.2024.104390_bib55","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.ijrobp.2021.07.297","article-title":"In-field failures in patients undergoing bridging radiotherapy for CD19-directed chimeric antigen receptor (CAR) T-cell therapy for recurrent\/refractory large B-cell lymphomas","volume":"111","author":"Sim","year":"2021","journal-title":"Int. J. Radiat. Oncol.\u00a0Biol.\u00a0Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib56","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ijrobp.2019.05.065","article-title":"Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma","volume":"105","author":"Sim","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib57","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1158\/2326-6066.CIR-18-0551","article-title":"BCMA-targeted CAR T-cell therapy plus radiation therapy for the treatment of refractory myeloma reveals potential synergy","volume":"7","author":"Smith","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib58","first-page":"69","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood\u00a0Cancer J."},{"key":"10.1016\/j.critrevonc.2024.104390_bib59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijrobp.2014.09.041","article-title":"Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma","volume":"91","author":"Tseng","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib60","first-page":"5607","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood\u00a0Adv."},{"key":"10.1016\/j.critrevonc.2024.104390_bib61","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.21873\/anticanres.15152","article-title":"Salvage radiation treatment for primary refractory diffuse large B-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy: a case report","volume":"41","author":"Wang","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib62","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2024.104390_bib63","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","article-title":"NKG2D-Based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma","volume":"78","author":"Weiss","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2024.104390_bib64","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2024.104390_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijrobp.2020.05.014","article-title":"Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma","volume":"108","author":"Wright","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib66","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/blood.2020009515","article-title":"Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy","volume":"138","author":"Wudhikarn","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2024.104390_bib67","article-title":"Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma upon anti-CD19 chimeric antigen receptor T therapy","author":"Yan","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib68","article-title":"Salvage radiotherapy for relapsed\/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy","volume":"39","author":"Yegya-Raman","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib70","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.radonc.2022.10.018","article-title":"Radiation prior to chimeric antigen receptor T-cell therapy is an optimizing bridging strategy in relapsed\/refractory aggressive B-cell lymphoma","volume":"177","author":"Yu","year":"2022","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104390_bib71","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"Zhang","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.critrevonc.2024.104390_bib72","article-title":"ICAM-1 orchestrates the abscopal effect of tumor radiotherapy","volume":"118","author":"Zhao","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2024.104390_bib73","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.ijrobp.2019.06.516","article-title":"Radiotherapy in combination with chimeric antigen receptor T cell therapy is a safe and promising approach in relapsed\/refractory diffuse large B cell lymphoma patients with high tumor burden","volume":"105","author":"Zhu","year":"2019","journal-title":"Int. J. Radiat. Oncol.\u00a0Biol.\u00a0Phys."},{"key":"10.1016\/j.critrevonc.2024.104390_bib74","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26718","article-title":"Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am. J. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824001331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T07:07:20Z","timestamp":1718867240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824001331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":74,"alternative-id":["S1040842824001331"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104390","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of radiation in chimeric antigen receptor T-cell therapy for patients with relapsed\/refractory non-Hodgkin lymphoma: Current studies and future prospects","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104390"}}